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Abstract:
Esophageal cancer incidence is rising and has few treatment options. In studying receptor tyrosine kinases associated with esophageal cancers, we have identified EPHB4 to be robustly over expressed in cell lines and primary tumor tissues. In total, 94 squamous cell carcinoma (SCC), 82 adenocarcinoma, 25 dysplasia, 13 Barrett's esophagus and 25 adjacent or unrelated normal esophageal tissues were evaluated by IHC. EPHB4 expression was significantly higher in all the different histologic categories compared to adjacent normal tissues. In 13 esophageal cancer cell lines, three of the nine SCC cell lines and one of the four adenocarcinomas expressed very high levels of EPHB4. An increased gene copy number ranging from 4-20 copies was identified in a subset of the overexpressing patient samples and cell lines. We have developed a novel 4-NQO induced mouse model of esophageal cancer that recapitulates the EPHB4 expression in humans. A specific small molecule inhibitor̘of EPHB4 decreased cell viability in a time and dose dependent manner in three of the four cell lines tested. The small molecule inhibitor and an EPHB4 siRNA also decreased cell migration (12-40% closure in treated vs. 60-Ǥ Ͷ ͳͲȀͳͻȀͳʹ ͷ in arterial endothelial cells (ECs), whereas EPHB4 is mostly venous-specific. Targeted inactivation of EPHB4 and EPHRINB2 have demonstrated that both are essential for angiogenic remodeling and embryonic survival (3, 4) . There are several signal transduction pathways and corresponding molecules that have been implicated in angiogenesis and tumorigenesis with regards to the Eph/ephrin axis (5) (6) (7) (8) (9) ; the Jak/Stat pathway, involved in cell growth and viability, is a novel signaling pathway of EphA4 (10) . The Akt/PI3K (phosphatidylinositol 3-kinase) is another signaling cascade involved in regulating cell proliferation and viability (reviewed in (11) ). A study by Steinle et al. (12) demonstrated that EPHB4 receptor signaling mediates endothelial cell migration and proliferation via the PI3K pathway (proliferation increased by 38% and migration by 63% upon EPHB4 activation with EPHRINB2). Signal transduction molecules inÀuencing cell motility includes paxillin, focal adhesion kinase (FAK), CRK, Rho, and P130Cas (13) (14) (15) .
Despite the progress made in understanding Eph/ephrin function in early developmental processes, as well as their role in cancer due to their complex nature, much remains to be understood about the mechanisms and signaling processes of Eph receptors.
In this study, we demonstrate that EPHB4 is over expressed and has increased gene copy numbers in esophageal cancer. We also report that EPHB4 is involved in enhanced motility and migration of cancer cells. These findings demonstrate that EPHB4 contributes to tumor biology.
In addition, we report the development of a carcinogen induced esophageal cancer mouse model that recapitulates EPHB4 expression in human disease, which will serve as a useful model in Ǥ Ͷ ͳͲȀͳͻȀͳʹ for esophageal cancer. Ultimately, EPHB4 represents a novel target for esophageal cancer.
Materials and Methods:
Cell lines: Esophageal cancer cell lines (FLO, Kyse-110, Kyse-140, Kyse-220, Kyse-410, Kyse-850, SKGT-4, TE-1, and TE-12) were cultured in DMEM or DMEM+Hank's F12 media supplemented with 10% FBS and penicillin in a 37°C, 5% CO 2 environment. The FLO cells were a kind gift from Dr. David Beers of University of Michigan, USA and the Kyse cells were acquired through a generous gift from Dr. Yutaka Shimada of Toyama University, Japan. The cell lines used in this study were not authenticated by any tests in our laboratory.
Tissue acquisition: Samples for this study were acquired from paraffin-embedded, formalinfixed tissues archived at The University of Chicago Human Tissue Resource Center (HTRC) available through IRB-approved protocols. Experienced pathologists (JM and MWL) analyzed samples using conventional light microscopy and determined the histological subtype as well as tumor grade.
Barrett's TMA
A Barrett's Esophagus Tissue Microarray (TMA) was created with samples selected from the archive: carcinoma (n=3), high-grade dysplasia HGD (n=15), low-grade dysplasia LGD (n=10), non-dysplastic Barrett's esophagus (n=13) and normal control (n=4; colon, placenta, liver, and kidney Briefly, following deparaffinization and quenching of endogenous peroxidase, sections were retrieved in a DAKO Target Retrieval Solution, transferred to the Dako Autostainer and incubated with the anti-EPHB4 antibody at 1:6 dilution for 30 min followed by Advance TM HRP detection system. Peroxidase reaction was developed using DAB provided in the kit and slides counterstained with Hematoxylin.
IHC for ephB4 on mouse esophagus (mice described later in in vivo methods) was performed similarly on the Dako Autostainer using polyclonal goat anti-ephB4 antibody (R&D # BAF446). Expression was also correlated with grade. Grades in each of the US Biomax TMAs were defined on an ordinal scale of 1-4. They were coded as well differentiated (1), moderately differentiated (2), poorly differentiated (3), and undifferentiated (4) . The data was analyzed using a bivariate correlation coefficient. A Spearman correlation coefficient was used and missing data were excluded pairwise. The correlation coefficient was calculated separately for squamous cell carcinomas and adenocarcinomas. To compare tumor and normal IHC data from US Biomax TMAs, a Mann Whitney test was performed on the 4 TMAs and EPHB4 expression in tumors correlated to that of normal samples in the corresponding TMA. There was no normal protein expression data available for BC2011 and BC2051. We acknowledge that the immunohistochemistry data was acquired by semi-quantitative analysis by a single pathologist to have no associated errors, and we have not done repeat experiments to show that they are reproducible.
Ǥ Ͷ ͳͲȀͳͻȀͳʹ ͻ
Immunoblot and phospho-protein immunoblot: Cells were lysed using RIPA buffer supplemented with sodium orthovanadate, protease and phosphatase inhibitors. 150 ug of total protein were subjected to SDS-PAGE on 7.5% gel, transferred to PVDF membranes, and probed with appropriate primary antibodies. After blocking with 5% BSA, bands were visualized using HRP-conjugated secondary antibodies exposed to 1:1 horseradish peroxidase ECL solutions (Bio-Rad Laboratories, Hercules, CA), and images were taken using chemiluminescent imaging system ChemiDoc™XRS (Bio-Rad). The non-small cell lung cancer (NSCLC) cell line H1993 was used as positive control in some blots. ȕ-actin or GAPDH served as loading controls.
Genomic DNA: Genomic DNA (gDNA) was collected according to procedures described previously (16) from a subset of the paraffin-embedded tissues utilized for EPHB4 IHC. The integrity of gDNA was evaluated by agarose gel electrophoresis followed by PCR with ȕ-globin.
Real-time quantitative PCR (RTQ-PCR):
Using a short target sequence within EPHB4, patient gDNA was used in RTQ-PCR to determine absolute gene copy number. Standard curves were generated using standard DNA to ensure a suitable range of sample detection; copy numbers were normalized to LINE-1 as a paired internal control. Samples and controls were amplified in triplicate. We interpreted this data descriptively by examining the relative frequencies of amplification status and noting remarkable findings. EPHB4 was considered amplified if its average detected gene copy number was greater than 4 copies. DNA extracted from H1993 served as positive control.
Research. Data was analyzed comparing the mean tumor volume of the two groups on day 37, and the P value was calculated with student T-test, 2 tailed.
in vivo model of esophageal carcinoma: Male CBA mice, 6-8 weeks, Jackson Laboratory (Bar Harbor, ME) were used for this study. Mice were administered 4-Nitroquinoline 1-oxide (4-NQO)
Research. Ǥ Ͷ ͳͲȀͳͻȀͳʹ ͳʹ in their drinking water on a continuous basis at 50 mg/ml for 8 weeks following protocols detailed previously (19) . Control mice were given vehicle only. Immediately following sacrifice, whole esophagi were paraffin embedded and sections evaluated for histological changes and ephb4 expression. Dysplasia was characterized as a lesion that demonstrated one or more histopathologic alterations and esophageal cancer was characterized by invasion into the underlying connective tissue, stroma, according to previously described criteria (19) .
Results:
EPHB4 protein is over expressed in esophageal cancer patient tissue samples: The EPHB4 protein is expressed in blood vessels, normal tissue and cancer cells and is detectable in cell membranes and cytoplasm. The samples in this study contained squamous cell carcinoma (94), adenocarcinoma (82), dysplasia (25), Barrett's esophagus (13) and adjacent or unrelated normal esophageal tissues (25) , all of which were evaluated for EPHB4 protein expression by immunohistochemistry using a specific antibody against EPHB4 ( Figure 1A ). The data were analyzed in batches depending on the availability of background information and are depicted in Figure   1C ). Kyse-220 and Kyse-410 were xenografted in nude mice and tumors evaluated for EPHB4; a strong membrane associated expression was evident in both ( Figure 1D ).
Variability of EPHB4 gene copy number in esophageal cancer patient samples: Gene copy number was determined using gDNA from 15 archival SCCs and 8 archival adenocarcinoma patient samples, commercially available normal human DNA and three individual normal esophageal tissue samples as internal reference controls. In SCCs, 9 of 15 (60%) patients had a gene copy number ranging from 4 and 20; similarly, in adenocarcinomas, 5 of 8 (62%) had gene copy number ranging from 4 to 20 (Figure 2A, 2B ). In addition, 33% of the SCC and 25% of the adenocarcinoma cell lines had copy numbers of 4 ( Figure 2C ). Control copy numbers were 2 in each case. In an effort to determine gene copy number changes in EPHRINB2, we also
Research. 
Ǥ Ͷ ͳͲȀͳͻȀͳʹ ͳͷ
The same experiment was repeated with SKGT-4, Kyse-110 and Kyse-410 cells transfected with siRNA targeted against EPHB4 or a scrambled siRNA and untransfected controls. The FLO cell line is a combination of adherent and suspension cells and presented a technical challenge. The experimental design of siRNA treatment followed by viability or wound healing assays rendered the acquired data unreliable due to uneven loss of suspension cells at each repeat instance. We lacked confidence in the consistency of the FLO data and decided not to use it. The gene specific silencing yielded similar inhibition of cell proliferation. This data suggests that EPHB4 is a target of the SMI ( Figure 3B ). Figure 4A 
Pharmacologic inhibition of EPHB4 inhibits cell migration:
Ǥ Ͷ ͳͲȀͳͻȀͳʹ ͳ
Chemical induction of esophageal carcinogenesis in a mouse model and ephb4 expression:
The mouse 4-NQO model development of oral and esophageal carcinogenesis has previously been described in detail by Tang et al. and us (19, 25, 26) . Here, we report esophageal SCC as a result of carcinogenic induction by 4-NQO ingestion and the expression of ephb4. In our model, 38% of mice developed invasive SCC, 29% carcinoma in situ, 24% dysplasia and only 9% remained any histologically unchanged ( Figure 7A and B) . Ten age-matched normal mice with no 4-NQO induction were used as normal controls; all 10 normal esophagi showed a score of 0 for ephb4 staining. Of the 21 4-NQO treated mouse esophagus, only 10 were used for IHC due to limitations of staining resources. Eight samples constituted invasive or early invasive cancer and had an average score of 1.8 while the remaining two were dysplasias with an average score of 3 ( Figure 7C ).
Discussion:
In determining the role of EPHB4 in esophageal cancer, we profiled its protein expression pattern and compared to adjacent normal tissue. We found that there was consistently higher expression of EPHB4 in both squamous cancer and adenocarcinoma compared to adjacent normal tissue. IHC data showed a significantly greater protein expression in tumor tissues compared to normal tissues. In addition, a significant correlation was established between EPHB4 expression and higher grade of SCC, suggesting that overexpression of EPHB4 in SCC plays a role in clinically aggressive tumors. We also detected a robust expression of EPHB4 in all of the 13 esophageal cancer cell lines. We further found that in more than 40% of SCC patients, the EPHB4 gene copy number ranged between 4 and 20 and more than 60% of patients (27, 28) . Although activating mutations are a potential method by which RTKs are constitutively activated in cancer, we did not detect any significant mutations in EPHB4 in cancer cells. Specific inhibition of EPHB4 by a small molecule inhibitor showed that in three out of four esophageal cancer cells, the drug impaired cell growth. Moreover, this compound also blocked migration in wound healing assay. Both of these phenomena were clearly reproduced by silencing EPHB4 with siRNA. These findings underscore that functional overexpression and EPHB4 activity are regulated by other oncogenic drivers, and that EPHB4 represents an important pathway to target in the treatment of esophageal cancers.
The expression of EPHB4 has been also shown to be higher in tumor tissues from lung, breast, prostate, bladder, ovarian, head and neck and colon cancers among others (29) (30) (31) (32) (33) . Esophageal cancers are a heterogeneous group of disorders reflecting both adenocarcinoma and SCC. In particular, as the lesion progresses from preneoplasia (Barrett's esophagus or dysplasia) to cancer, EPHB4 expression increases. Interestingly, the gene copy number was also increased in several tumor specimens. This could either represent polysomy or clustered amplification. It would be important to perform further studies using a FISH analysis and compare with copy number of other genes, such as MET and Her2/neu that can be abnormal in adenocarcinomas.
Ǥ Ͷ ͳͲȀͳͻȀͳʹ ͳͻ
EPHB4 has been reported to possess tumor suppressor properties (34). However, as shown here, a small molecule inhibitor against EPHB4 or depletion with siRNA leads to a decrease in cell growth and viability. It would be important to study the effects of EPHB4 in combination with cytotoxic chemotherapy or radiation therapy, as well as to conduct in vivo studies to validate these findings.
In generating a mouse model to study esophageal carcinoma, we were successful in showing that the 4-NQO model of oral carcinogenic induction resulted in high incidence of squamous cell cancer development. In addition, the progressive induction of carcinogenic changes makes this an ideal model for prevention studies. For the first time, we were able to utilize this mouse model to demonstrate that ephb4 is overexpressed in squamous cell carcinoma as compared to normal esophagus. Moreover, in xenograft tumor model of FLO cells, we were able to see a large reduction in tumor volume with an EPHB4 inhibitor in vivo. The 4-NQO mouse model will significantly enhance not only the study of molecular markers such as EPHB4, but will also help to define progression, invasion, angiogenesis and possibly metastasis related biological changes in this histology. This model will be also useful in future studies using inhibitors or EPHB4.
One of the features of esophageal squamous cell carcinoma is the division of its incidence into low and high risk areas, based on geographical location. Some of the low risk areas include North America, along with countries in Western Asia and Northern and Southern Europe, where the incidence rates range from 1.5 to 6.0/100,000. High risk areas include South Africa, China, Iran and countries in Eastern Africa, where the incidence rates range from 10 to 25/100,000 (35, 36) . In addition to the known risk factors such as alcohol and tobacco, GERD, nutritional (37, 38) . Interestingly, the highest frequencies of HPV infection are seen in the high risk geographical locations. HPV infection has been implicated in other squamous cell carcinomas such as head and neck cancer (21) , and non-melanoma skin cancer (39) (40) (41) , and its involvement in cervical cancer is well established (42) . We tested ten representative esophageal SCC samples and their adjacent normal tissues of which six were African American and four Caucasian. None of the samples tested positive for HPV. In the past, it has been proposed that esophageal squamous cell cancer can have HPV positivity. However, we did not identify this in our population.
Our study shows that, not only is EPHB4 important in cell growth, but also in cell motility and migration in several cell lines. This is most likely related to the cytoskeletal function, especially formation of focal adhesion complexes. With inhibition of EPHB4, there was decreased phosphorylation of p125FAK. FAK is a focal adhesion protein that is important both structurally and functionally. It is predicted that the EPHB4 molecule may be tightly linked to other proteins such as p130cas and paxillin. Previously, we have identified paxillin to be over expressed or mutated in NSCLC. It would be important to study this molecule in the context of EPHB4 in the future.
With increased motility and migration, tumors also gain more invasive properties that could lead to metastasis. Local proliferation and growth of tumor, invasion and metastasis also leads to angiogenesis in the tumor bed. Since EPHB4 and its ligand, EPHRINB2, also participate in Our results that one of the cell lines which was resistant to EPHB4 in vitro responded to the inhibition of EPHB4 pathway in vivo, supports this hypothesis.
In summary, we have identified EPHB4 to be a key participant in esophageal pre-neoplastic and neoplastic lesions. It would be useful to explore EPHB4 inhibition strategy to clinical fruition in esophageal cancer.
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